Department of Cell and Molecular Biology& Microbiology, Faculty of Science and Technology, University of Isfahan, Isfahan, IR, Iran.
PLoS One. 2023 Aug 10;18(8):e0289247. doi: 10.1371/journal.pone.0289247. eCollection 2023.
Autosomal recessive non-syndromic hearing loss (ARNSHL) is a public health concern in the Iranian population, with an incidence of 1 in 166 live births. In the present study, the whole exome sequencing (WES) method was applied to identify the mutation spectrum of NSHL patients negative for GJB2 gene mutations. First, using ARMS PCR followed by Sanger sequencing of the GJB2 gene, 63.15% of mutations in patients with NSHL were identified. Among the identified mutations in GJB2:p.Val43Met and p.Gly21Arg were novel. The remaining patients were subjected to WES, which identified novel mutations including MYO15A:p.Gly39LeufsTer188, ADGRV1:p.Ser5918ValfsTer23, MYO7A: c.5856+2T>c (splicing mutation), FGF3:p.Ser156Cys. The present study emphasized the application of WES as an effective method for molecular diagnosis of NSHL patients negative for GJB2 gene mutations in the Iranian population.
常染色体隐性非综合征型听力损失(ARNSHL)是伊朗人群中的一个公共健康问题,发病率为每 166 例活产儿中有 1 例。在本研究中,采用外显子组测序(WES)方法来确定 GJB2 基因突变阴性的 NSHL 患者的突变谱。首先,通过 ARMS-PCR 并对 GJB2 基因进行 Sanger 测序,确定了 63.15%的 NSHL 患者存在基因突变。在鉴定出的 GJB2 基因突变中,p.Val43Met 和 p.Gly21Arg 是新发现的突变。其余患者进行了 WES,鉴定出了包括 MYO15A:p.Gly39LeufsTer188、ADGRV1:p.Ser5918ValfsTer23、MYO7A:c.5856+2T>C(剪接突变)和 FGF3:p.Ser156Cys 在内的新突变。本研究强调了 WES 作为一种有效的方法,可用于对伊朗人群中 GJB2 基因突变阴性的 NSHL 患者进行分子诊断。